GSK press releases Follow FDA grants priority review of Nucala for patients with Hypereosinophilic Syndrome (HES) An approval would give Nucala a third indication in an eosinophil-driven disease https://www.gsk.com/en-gb/media/press-releases/fda-grants-priority-review-of-nucala-for-patients-with-hypereosinophilic-syndrome-hes/ gsk.com
